CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts

[1]  P. Guglielmelli,et al.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. , 2014, Blood.

[2]  F. Passamonti,et al.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons , 2014, Leukemia.

[3]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[4]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[5]  A. Tefferi,et al.  Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance , 2013, American journal of hematology.

[6]  A. Tefferi,et al.  SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients , 2012, Leukemia.

[7]  G. Garcia-Manero,et al.  SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. , 2012, Blood.

[8]  A. Tefferi,et al.  Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients , 2011, Leukemia.

[9]  A. Tefferi,et al.  Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. , 2011, Blood.

[10]  A. Schmitt-Graeff,et al.  Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. , 2002, Haematologica.